Hip Osteoarthritis in Dogs: A Randomized Study Using Mesenchymal Stem Cells from Adipose Tissue and Plasma Rich in Growth Factors

International Journal of Molecular Sciences

Belen Cuervo³  Monica Rubio³  Joaquin Sopena³  Juan Manuel Dominguez⁴  Jose Vilar²  Manuel Morales²  Ramón Cugat¹ 

[1] Garcia Cugat Foundation CEU UCH Chair of Medicine and Regenerative Surgery, 08006 Barcelona, Spain; E-Mail:;Department of Animal Medicine and Surgery, University of Las Palmas de Gran Canaria, 35413 Las Palmas de Gran Canaria, Spain; E-Mails:;Department of Animal Medicine and Surgery, CEU Cardenal Herrera University, C/Tirant lo Blanc, 7, 46115 Alfara del Patriarca, Valencia, Spain; E-Mails:;Department of Animal Medicine and Surgery, University of Cordoba, 14071 Cordoba, Spain; E-Mail:

关键词: adipose derived mesenchymal stem cells;    plasma rich in growth factors;    osteoarthritis;    dog;    hip;   

DOI  :  10.3390/ijms150813437

来源: mdpi

【 摘 要 】

Purpose: The aim of this study was to compare the efficacy and safety of a single intra-articular injection of adipose mesenchymal stem cells (aMSCs) versus plasma rich in growth factors (PRGF) as a treatment for reducing symptoms in dogs with hip osteoarthritis (OA). Methods: This was a randomized, multicenter, blinded, parallel group. Thirty-nine dogs with symptomatic hip OA were assigned to one of the two groups, to receive aMSCs or PRGF. The primary outcome measures were pain and function subscales, including radiologic assessment, functional limitation and joint mobility. The secondary outcome measures were owners’ satisfaction questionnaire, rescue analgesic requirement and overall safety. Data was collected at baseline, then, 1, 3 and 6 months post-treatment. Results: OA degree did not vary within groups. Functional limitation, range of motion (ROM), owner’s and veterinary investigator visual analogue scale (VAS), and patient’s quality of life improved from the first month up to six months. The aMSCs group obtained better results at 6 months. There were no adverse effects during the study. Our findings show that aMSCs and PRGF are safe and effective in the functional analysis at 1, 3 and 6 months; provide a significant improvement, reducing dog’s pain, and improving physical function. With respect to basal levels for every parameter in patients with hip OA, aMSCs showed better results at 6 months.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.